Intercept Pharmaceuticals, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.

In the transaction, Intercept stockholders are expected to receive only $19 per share in cash. The transaction agreement unreasonably limits competing transactions for Intercept by imposing a significant penalty if Intercept accepts a competing bid. Intercept insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Intercept’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.